Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 24 |
| Active Pipeline (Recruiting Now) | 12 (9) |
| Completed vs Stopped Early | 1 / 0 (0.0%) |
| Median Closed Actual Enrollment | 100 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Chinese PLA General Hospital | Beijing | 2 |
| The First Hospital of Lanzhou University | Lanzhou, Gansu | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Beijing 302 Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.